Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y (2021) GLP-1 receptor agonists: beyond their pancreatic effects
It has also been approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or have obesity
Preliminary program results are promising: ~1,500 clients have enrolled in the program since the program launched in April 2023, including: 61% of commercial employer-sponsored lives 17% of commercial health plan lives ** 67% of members meet smart logic criteria and do not require submission of a PA request 84% of PA requests result in denial, and 72% overall target fill rate *** ~$1B or ~$4.86 PMPM in client savings 3 These drugs are being studied in both weight- and non-weight-related conditions
Long-term sustainability and relapse prevention represent distinct clinical challenges which are addressed in the following chapter
doi:10.1007/s00125-011-2204-7 12
Also see other tips for the best way to prepare brewable green tea, and our Top Picks among green tea products
